Coagulation Factor Ix Human

Summary

Coagulation Factor Ix Human (CHEMBL4297986) is an approved unknown; indicated across 2 conditions including hemophilia b and coagulation protein disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297986
Name	Coagulation Factor Ix Human
Type	Unknown
Max phase	4

Also known as: Coagulation factor ix human, Factor ix human, Human coagulation factor ix, Mononine, Nonafact, Replenine, COAGULATION FACTOR IX HUMAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
hemophilia B	4	MONDO:0010604	MONDO:0010604
coagulation protein disease	4	MONDO:0002242

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00139828	PHASE4	COMPLETED	Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).